Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azeliragon with CSI in Leptomeningeal Metastasis
NCT06724926Phase 1Active, not recruiting
- Sponsor
- NYU Langone Health
- Start
- Feb 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azeliragon in leptomeningeal metastasis (LM), sponsored by NYU Langone Health. Primary endpoints: Number of Patients with Dose-Limiting Toxicities at Dose Level 1 at 4 weeks, Number of Patients with Dose-Limiting Toxicities at Dose Level -1 at 4 weeks and 1 more. Started Feb 2025; status: active, not recruiting.
02
Drugs
azeliragon
03
Conditions
leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06724926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724926.